| Title: |
The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers |
| Authors: |
Bancroft, EK; Page, EC; Brook, MN; Pope, J; Thomas, S; Myhill, K; Helfand, BT; Talaty, P; Ong, KR; Douglas, E; Cook, J; Rosario, DJ; Salinas, M; Buys, SS; Anson, J; Davidson, R; Longmuir, M; Side, L; Eccles, DM; Tischkowitz, M; Taylor, A; Cruellas, M; Ballestero, EP; Cleaver, R; Varughese, M; Barwell, J; LeButt, M; Greenhalgh, L; Hart, R; Azzabi, A; Jobson, I; Cogley, L; Evans, DG; Rothwell, J; Taylor, N; Hogben, M; Saya, S; Kote-Jarai, Z; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, C; Grönberg, H; Hamdy, FC; Jóhannsson, ÓÞ; Khoo, V; Lilja, H; Lindeman, G; Lubinski, J; Maehle, L; Millner, A; Mikropoulos, C; Mitra, A; Moynihan, C; Offman, J; Rennert, G; Suri, M; Wilson, P; Melia, J; Mitchell, G; Moss, S; Schroder, F; Easton, D; Peock, S; Sibley, P; Sharifi, R; James, P; Shanley, S; Richardson, K; McKinley, J; Petelin, L; Murphy, M; Mascarenhas, L; Reeve, K; Murphy, D; Lam, J; Chong, M; Suthers, G; Poplawski, N; Ward, R; Tucker, K; Andrews, L; Williams, R; Duffy, J; Millard, R; Jarvis, T; Stricker, P; Kirk, J; Bowman, M; Patel, M; Harris, M; O'Connell, S; Hunt, C; Smyth, C; Frydenberg, M; Morton, C; Shackleton, K |
| Publisher Information: |
Wiley |
| Publication Year: |
2024 |
| Collection: |
The University of Melbourne: Digital Repository |
| Description: |
OBJECTIVES: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the 'Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls' (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2). SUBJECTS AND METHODS: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge. RESULTS: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time. CONCLUSION: This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISSN: |
1464-4096 |
| Relation: |
https://hdl.handle.net/11343/351311 |
| Availability: |
https://hdl.handle.net/11343/351311 |
| Rights: |
https://creativecommons.org/licenses/by/4.0 ; CC BY |
| Accession Number: |
edsbas.B93A8377 |
| Database: |
BASE |